ArticleBMC microbiology2026
Effects of low-dose dietary antimicrobial peptide Scy-hepc on disease resistance in Larimichthys crocea under secondary infection.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroudSecondary infection by Vibrio parahaemolyticus, triggered by Cryptocaryon irritans, has become one of the most difficult diseases to control in Larimichthys crocea aquaculture due to its complex pathogens and diverse infection mechanisms. Traditional antibiotic therapies often face challenges such as resistance and low efficacy. Previous studies have shown that the antimicrobial peptide (AMP) Scy-hepc has potential as an immune-enhancing alternative to antibiotics. This study identified typical features of a natural outbreak of V. parahaemolyticus secondary infection triggered by C. irritans in a marine aquaculture farm. Under these practical farming conditions, the overall protective efficacy and potential mechanisms of Scy-hepc were further evaluated.
resultsCompared to the same dosage of Vector, Florfenicol, Bacillus subtilis, and a basal diet (Control), Scy-hepc significantly improved the survival rate and increased the total body weight of L. crocea. qPCR results showed that Scy-hepc downregulated pro-inflammatory genes (IL-1β, TNF-α) and upregulated anti-inflammatory genes (TGF-β, IL-10) as well as the AMP genes (Hepcidin, NK-lysin). 16S rRNA sequencing revealed that although all groups experienced gut microbiota disruption due to infection, the gut microbiota in the Scy-hepc group was enriched with more specific microorganisms, characterized by an increased abundance of potential probiotics (Tenericutes, Bacillaceae, Bacteroidales) and a decreased relative abundance of opportunistic pathogens (Clostridiales, Fusobacteriaceae, Spirochaetes, and Vibrionaceae). Scy-hepc also enhanced microbial functions related to metabolism and immunity. Network analysis showed higher complexity and stability in the Scy-hepc group than in the Vector and Control groups. Mantel test analysis revealed that gut microbiota composition was significantly correlated with health-related indicators (survival rate and body weight) as well as immune-related indicators (NK-lysin, Hepcidin, GPx-1a, and CAT) in the Scy-hepc group.
conclusionsOverall, this study provides the potential evidence of Scy-hepc’s protective effects and potential mechanisms against secondary infection under practical farming conditions. These findings support its potential as a promising antibiotic alternative to promote the sustainable and healthy aquaculture of L. crocea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.